Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) rose 9.4% on Thursday . The company traded as high as $25.94 and last traded at $25.89. Approximately 1,203 shares were traded during trading, a decline of 99% from the average daily volume of 157,631 shares. The stock had previously closed at $23.67.
Aerovate Therapeutics Trading Up 0.1 %
The business has a fifty day moving average price of $15.73 and a two-hundred day moving average price of $13.59.
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.19). As a group, analysts expect that Aerovate Therapeutics, Inc. will post -1.82 EPS for the current fiscal year.
Institutional Inflows and Outflows
Aerovate Therapeutics Company Profile
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
- Get a free copy of the StockNews.com research report on Aerovate Therapeutics (AVTE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.